Study On The Correlation Between GFAP And S100B Protein Levels In Serum And Cognitive Function In Patients With Alzheimer’s Disease

Objective To investigate the correlation between serum glial fibrillary acidic protein(GFAP),S100B concentration and cognitive function in patients with Alzheimer’s disease.Methods For 100 patients with Alzheimer’s disease diagnosed in our hospital and 100 health check-ups,the cognitive function was assessed by the MMSE of simple mental state evaluation scale,Combined with clinical dementia rating scale(CDR)patients were divided into mild,moderate and severe AD groups,Of these,28 cases were mild AD,38 cases were moderate AD,34 cases in severe AD group.Classification criteria:mild dementia CDR=0.5-1;(b)Moderate dementia CDR=2;Severe dementia CDR=3,The serum GFAP and S100B concentration of every groups were detected by enzyme linked immunosorbent assay(ELISA)method.Results:1.Age,years of education,and the prevalence of hypertension,hyperlipidemia,diabetes in AD and control groups All cases had no significant difference(P>0.05)2.The MMSE score of the AD group was significantly lower than that of the healthy control group(P<0.05),and the difference between the two groups was statistically significant(P<0.05)3.The GFAP concentration of AD group was higher than that of the control group(P<0.05),and the GFAP concentration of mild,moderate and severe AD patients were higher than those of the control group(P<0.05).4.The S100B concentration of AD group was higher than that of the control group(P<0.05),and the S100B concentration of mild,moderate and severe AD patients were higher than those of the control group(P<0.05).5.Spearman correlation coefficient was used to analyse the correlation between serum GFAP and S100B protein levels and cognitive function of patients,GFAP levels were negatively correlated with MMSE(R=-0.83,P<0.01),S100B levels were negatively correlated with MMSE(R=-0.75,P<0.01).6.Analysis of Serum GFAP and S100B concentration for AD prediction:the results of ROC curve showed that the area under the ROC curve of serum GFAP、S100B level prediction was 0.944 and 0.917.Both have very good diagnostic ability to AD.Conclusion The increase of serum GFAP、S100B levels in patients with Alzheimer’s disease were related to the decline of cognitive function.The increase of serum GFAP、S100B level was a risk factor for cognitive dysfunction and may aggravate cognitive impairment.Detection of serum GFAP and S100B concentrations may contribute to early diagnosis and prevention of AD,and it may also assist clinicians in determining the severity of the disease.